A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174
Authors:
Hua-Jay J Cherng
Stefan K Alig
Yasuhiro Oki
Loretta J Nastoupil
Luis Fayad
Sattva S Neelapu
Francesco Turturro
Fredrick Hagemeister
Alexander F M Craig
Charles W Macaulay
Maria Alma Rodriguez
Hun Ju Lee
Timothy J McDonnell
Christopher R Flowers
Francisco Vega
Michael R Green
Lei Feng
David M Kurtz
Ash A Alizadeh
R Eric Davis
Jason R Westin
Affiliated Authors:
Hua-Jay J Cherng
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2022008174
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: